Charissa Y Chang

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi Review article: drug hepatotoxicity
    C Y Chang
    The Division of Liver Diseases, Department of Internal Medicine, The Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Aliment Pharmacol Ther 25:1135-51. 2007
  2. ncbi Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria
    Charissa Y Chang
    Recanati Miller Transplant Institute, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, NY, USA
    Liver Transpl 13:1532-7. 2007
  3. ncbi Patient with hepatitis B and alcoholic liver disease before and after liver transplantation
    Stephen C Ward
    The Lillian and Henry M Stratton Hans Popper Department of Pathology, The Mount Sinai Medical Center, New York, New York 10029, USA
    Semin Liver Dis 29:233-7. 2009
  4. ncbi Molecular approaches to treatment of hepatocellular carcinoma
    Anja Lachenmayer
    Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA
    Dig Liver Dis 42:S264-72. 2010
  5. ncbi A patient with chronic hepatitis B and regression of fibrosis during treatment
    Charissa Y Chang
    Division of Liver Diseases, Recanati Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY 10001, USA
    Semin Liver Dis 30:296-301. 2010
  6. ncbi Therapy of NAFLD: antioxidants and cytoprotective agents
    Charissa Y Chang
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-0708, USA
    J Clin Gastroenterol 40:S51-60. 2006

Detail Information

Publications6

  1. ncbi Review article: drug hepatotoxicity
    C Y Chang
    The Division of Liver Diseases, Department of Internal Medicine, The Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Aliment Pharmacol Ther 25:1135-51. 2007
    ..Drug toxicity is the leading cause of acute liver failure in the United States. Further understanding of hepatotoxicity is becoming increasingly important as more drugs come to market...
  2. ncbi Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria
    Charissa Y Chang
    Recanati Miller Transplant Institute, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, NY, USA
    Liver Transpl 13:1532-7. 2007
    ....
  3. ncbi Patient with hepatitis B and alcoholic liver disease before and after liver transplantation
    Stephen C Ward
    The Lillian and Henry M Stratton Hans Popper Department of Pathology, The Mount Sinai Medical Center, New York, New York 10029, USA
    Semin Liver Dis 29:233-7. 2009
    ..We discuss the interaction of alcoholic liver disease and hepatitis B virus in the development of cirrhosis and hepatocellular carcinoma, as well as the role of liver transplantation in these patients...
  4. ncbi Molecular approaches to treatment of hepatocellular carcinoma
    Anja Lachenmayer
    Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA
    Dig Liver Dis 42:S264-72. 2010
    ..In this article we review the current knowledge of the molecular pathogenesis of HCC and provide an overview of molecular targeted therapies in the management of HCC...
  5. ncbi A patient with chronic hepatitis B and regression of fibrosis during treatment
    Charissa Y Chang
    Division of Liver Diseases, Recanati Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY 10001, USA
    Semin Liver Dis 30:296-301. 2010
    ..Lengthy antiviral treatment can achieve resorption of excess fibrous tissue, even in patients with marked fibrosis...
  6. ncbi Therapy of NAFLD: antioxidants and cytoprotective agents
    Charissa Y Chang
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-0708, USA
    J Clin Gastroenterol 40:S51-60. 2006
    ..Particular promise may exist in the use of these agents in combination therapy with ones that target other aspects in the pathogenesis of NAFLD, such as insulin-sensitizing agents...